Abstract
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML). However, TKI-related chronic renal toxicity has been reported, particularly in patients with hypertension. We assessed whether incidental use of specific types of antihypertensive drugs, including renin–aldosterone–angiotensin system inhibitors (RAASis), affects the change in estimated glomerular filtration rate (eGFR) during TKI treatment. We retrospectively analyzed all eGFR measurements during TKI treatment for 142 CML patients at Kyushu University Hospital, estimating the rate of eGFR change using a mixed-effects model. Overall, a significant interaction was found between the type of antihypertensive medication used and the yearly change in eGFR (P < 0.01), with RAASi users exhibiting the most rapid decrease in eGFR (− 5.5%/year). The analysis by TKI used showed that the interaction was significant only in imatinib and bosutinib users (P < 0.01 and P = 0.04, respectively). The yearly rate of eGFR decrease was the most notable in RAASi users, at − 5.7 (− 6.6, − 4.9) and − 10.1 (− 12.3, − 7.9) for imatinib and bosutinib users, respectively. Our findings indicate that eGFR should be carefully monitored in patients taking these TKIs.
Similar content being viewed by others
References
O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994–1004.
Kantarjian H, Giles F, Wunderle L, Bhalla K, O’Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354(24):2542–51.
Talpaz M, Shah MP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354(24):2531–41.
Cortes JE, Kantarjianan HM, Brümmendorf TH, Kim DW, Turkina AG, Shen ZX, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118(17):4567–76.
Saglio G, Kim D-W, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251–9.
Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260–70.
Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: Results from the randomized BFORE trial. J Clin Oncol. 2018;36(3):231–7.
O’Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401–12.
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783–96.
Zeng P, Schmaier A. Ponatinib and other CML tyrosine kinase inhibitors in thrombosis. Int J Mol Sci. 2020;21(18):1–16.
Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8):1648–71.
Marcolino MS, Boersma E, Clementino NCD, Macedo AV, Marx-Neto AD, Silva MHCR, et al. Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Ann Oncol. 2011;22(9):2073–9.
Yilmaz M, Lahoti A, O’Brien S, Nogueras-González GM, Burger J, Ferrajoli A, et al. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Cancer. 2015;121(21):3894–904.
Hino A, Yoshida H, Tada Y, Koike M, Minami R, Masaie H, et al. Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia. Int J Hematol. 2016;104(5):605–11.
Ren X, Qin Y, Huang X, Zuo L, Jiang Q. Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors. Ann Hematol. 2019;98(7):1627–40.
Okamoto S, Ureshino H, Kawaguchi A, Miyazono M, Ikeda Y, Kimura S. Assessment of estimated glomerular filtration rate in patients with chronic myeloid leukemia following discontinuation of tyrosine kinase inhibitors. Int J Hematol. 2020;112(1):41–5.
Fox CS, Larson MG, Leip EP, Culleton B, Wilson PWF, Levy D. Predictors of new-onset kidney disease in a community-based population. J Am Med Assoc. 2004;291(7):844–50.
Jain P, Kantarjian H, Boddu PC, Nogueras-González GM, Verstovsek S, Garcia-Manero G, et al. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv. 2019;3(6):851–61.
Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42(9):1235–481.
Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982–92.
Vandenbroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology. 2007;18(6):805–35.
Katz MH. Multivariable analysis: a practical guide for clinicians and public health researchers. 3rd ed. Cambridge: Cambridge University Press; 2011. p. 197–200.
Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713–35.
Cortes JE, Gambacorti-Passerini C, Kim DW, Kantarjian HM, Lipton JH, Lahoti A, et al. Effects of bosutinib treatment on renal function in patients with Philadelphia chromosome-positive leukemias. Clin Lymphoma Myeloma Leuk. 2017;17(10):684-695.e6.
Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–40.
Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–54.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.
Mohanavelu P, Mutnick M, Mehra N, White B, Kudrimoti S, Kluesner KH, et al. Meta-analysis of gastrointestinal adverse events from tyrosine kinase inhibitors for chronic myeloid leukemia. Cancers (Basel). 2021;13(7):1–13.
Mansfield KE, Douglas IJ, Nitsch D, Thomas SL, Smeeth L, Tomlinson LA. Acute kidney injury and infections in patients taking antihypertensive drugs: a self-controlled case series analysis. Clin Epidemiol. 2018;10:187–202.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Mariko Tsuda received honoraria/lecture fees from Otsuka related to this study. Sojiro Haji received honoraria/lecture fees from Kyowa Kirin unrelated to this study. Yasuhiro Nakashima received research grants from the Japanese Society of Hematology, and research grant supports from Chugai, Kyowa Kirin, Daiichi Sankyo and SRL, honoraria/lecture fees from Otsuka related to this study, and Chugai, Kyowa Kirin, Ono and Sanofi, unrelated to this study. Motoaki Shiratsuchi received research grant supports from Chugai, Kyowa Kirin, Daiichi Sankyo, MSD and SRL, honoraria/lecture fees from Otsuka related to this study, and Chugai, Kyowa Kirin, Ono and Sanofi, unrelated to this study. Koji Kato received research grant supports from Chugai, Takeda, Kyowa Kirin, AbbVie, Novartis, Eisai, Janssen, Celgene, Ono and Daiichi Sankyo, honoraria/lecture fees from Kyowa Kirin, Novartis, Takeda and Chugai, unrelated to this study. Toshihiro Miyamoto received honoraria/lecture fees from Takeda, Otsuka, MSD, Kyowa Kirin, Janssen, Astellas and AbbVie. Koichi Akashi received research grant supports from Otsuka, Nippon Shinyaku, Taiho, Asahi Kasei, Chugai, Takeda, Kyowa Kirin, AbbVie, Sumitomo Dainippon, Astellas, Bristol Myers Squibb and Eisai, honoraria/lecture fees from AbbVie, Eisai, Ono, Kyowa Kirin, Chugai, Pfizer, Bristol Myers Squibb and Janssen, unrelated to this study. Naoki Nakashima received research grant supports from Pfizer unrelated to this study. Yoshihiro Ogawa received research grant supports from Kyowa Kirin, Taisho, Mochida, Cosmic Corporation, Fujifilm, Mitsubishi Tanabe, AstraZeneca, Nippon Boehringer lngelheim, Eisai, Abbott, Chugai, Pfizer, Tsumura, Otsuka, Taiho, Zeria and Fujiyakuhin, honoraria/lecture fees from Novo Nordisk Pharma and Taisho, unrelated to this study. The other authors have no conflicts of interest to declare.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Tsuda, M., Hirata, A., Tokunaga, S. et al. Rapid decrease in eGFR with concomitant use of tyrosine kinase inhibitors and renin–aldosterone–angiotensin system inhibitors in patients with chronic myelogenous leukemia. Int J Hematol 116, 863–870 (2022). https://doi.org/10.1007/s12185-022-03433-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-022-03433-6